Gaines v. AstraZeneca Pharmaceutical

District Court, S.D. New York·Decided October 12, 2021·No. 1:21-cv-05323·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ERNEST EDWARD GAINES, Plaintiff, -against- 21-CV-5323 (LTS) ASTRAZENECA PHARMACEUTICAL; ORDER TO AMEND FERRER, POIROT & WANSBROUGH; HOWARD L. NATIONS, Defendants. LAURA TAYLOR SWAIN, Chief United States District Judge: Plaintiff, who is incarcerated in the custody of the Texas Department of Criminal Justice in Lamesa, Texas, is proceeding pro se and in forma pauperis. Plaintiff sues attorney Howard Nations, the law firm Ferrer, Poirot & Wansbrough, and Astrazeneca Pharmaceuticals, LP. By order dated July 26, 2021, the Court directed Plaintiff to submit a declaration showing cause why the Court has subject matter jurisdiction of this action. Plaintiff filed a declaration on September 28, 2021, and the Court has reviewed it. For the reasons set forth below, the Court grants Plaintiff leave to file an amended complaint within 30 days of the date of this order. STANDARD OF REVIEW The Prison Litigation Reform Act requires that federal courts screen complaints brought by prisoners who seek relief against a governmental entity or an officer or employee of a governmental entity. See 28 U.S.C. § 1915A(a). The Court must dismiss a prisoner’s in forma

pauperis complaint, or any portion of the complaint, that is frivolous or malicious, fails to state a claim upon which relief may be granted, or seeks monetary relief from a defendant who is immune from such relief. 28 U.S.C. §§ 1915(e)(2)(B), 1915A(b); see Abbas v. Dixon, 480 F.3d 636, 639 (2d Cir. 2007). The Court must also dismiss a complaint if the court lacks subject matter jurisdiction. See Fed. R. Civ. P. 12(h)(3). BACKGROUND Plaintiff Ernest Gaines alleges the following in his complaint. Attorney Howard Nations filed a class action suit in the New York Supreme Court, New York County, Fishman et al. v.

Astrazeneca Pharmaceuticals, LP, et al., Index No. 09109049 (N.Y. Sup. Ct.), on behalf of Plaintiff and others, alleging that they were inadequately warned about potential harm from the drug Seroquel. (ECF 2-1 at 38). One or more attorneys from the law firm of Ferrer, Poirot & Wansbrough also appeared on behalf of the plaintiff class. As of the date the class action settled in 2012, Plaintiff suffered from “hyperglycemia” but had not been diagnosed with diabetes. (ECF 2 at 4.) Counsel notified class members that recovery for the suit was less than expected because of difficulties proving that Seroquel had caused the class members’ injuries. Plaintiff’s share of the settlement was $11,214.95, and after deduction of attorney’s fees and costs, he received a settlement payment of $6,336.71. At some point, Plaintiff came across a 2011 news article that stated that the “average

payout” in class action litigation about Seroquel was approximately $25,000. (Id. at 40). Plaintiff writes that attorney “Howard Nations really shortage me by $14,000.” (Id. at 15.) After Plaintiff received payout of the settlement, in 2014, he was diagnosed with diabetes. (Id.) Plaintiff contends that Seroquel damaged his pancreas, causing his diabetes. (Id.) Plaintiff argues that even “$500,000 is really not enough” to settle his claims, because he has “to live with this condition for the rest of [his] life.” (Id.) He contends that “Mr. Nations misinformed/malpractice me of the damage this medication really capable of causing.” (Id.) After settlement, Plaintiff sent letters and other documents to class counsel and the state court. The documents that he sent to the state court were captioned for the “United States Supreme Court for the State of New York” or “United States District Court for the State of New York” (ECF 2-1 at 1); the state court, apparently understanding that Plaintiff intended to file in federal court because his papers were captioned for a court of the “United States,” directed Plaintiff to send his papers to this court. (Id. at 23, 29, 46.)

By order dated July 26, 2021, the Court notified Plaintiff of the legal standards for establishing federal question and diversity jurisdiction. The Court also explained that Plaintiff could drop any defendant who destroyed diversity jurisdiction, so long as the defendant was not indispensable. The Court granted Plaintiff an opportunity to submit a declaration showing that the Court had subject matter jurisdiction of this action. The Court also raised the likelihood that Plaintiff could not relitigate the same claims that he had already settled. DISCUSSION A. Diversity of Citizenship As set forth in the Court’s July 26, 2021 order, the subject matter jurisdiction of federal courts is limited. (ECF 8.) Jurisdiction is available in federal court only when a “federal question” is presented, 28 U.S.C. § 1331, or when plaintiff and defendant are citizens of different

states and the amount in controversy exceeds $75,000, 28 U.S.C. § 1332. “If the court determines at any time that it lacks subject-matter jurisdiction, the court must dismiss the action.” Fed. R. Civ. P. 12(h)(3). In his September 28, 2021 declaration, Plaintiff invokes the Court’s diversity jurisdiction, and the Court therefore considers whether Plaintiff and the defendants are citizens of different states. Wis. Dep’t of Corr. v. Schacht, 524 U.S. 381, 388 (1998). For diversity purposes, an individual is a citizen of the State where he is domiciled. Palazzo ex rel. Delmage v. Corio, 232 F.3d 38, 42 (2d Cir. 2000) (internal quotation marks and citation omitted) (defining domicile as the place where a person “has his true fixed home . . . and to which, whenever he is absent, he has the intention of returning.”). A corporation is a citizen “of every State and foreign state by which it has been incorporated and of the State or foreign state where it has its principal place of business,” § 1332(c)(1),1 and a limited partnership or other unincorporated entity possesses the citizenship of each of its members, Americold Realty Trust v. Conagra Foods, Inc., 577 U.S. 378,

383 (2016). See also Carden v. Arkoma Assocs., 494 U.S. 185, 195 (1990) (adhering to the “oft- repeated rule” that courts must “count every member of an unincorporated association for purposes of diversity jurisdiction”); Handelsman v. Bedford Vill. Associates Ltd. P’ship, 213 F.3d 48, 52 (2d Cir. 2000) (holding that a limited partnership has the citizenship of each of its general and limited partners). In his declaration, Plaintiff avers that he resides in and is a citizen of Texas. He refers to Defendant Astrazeneca Pharmaceuticals for the first time as “LP,” that is, as a limited partnership, which is an unincorporated entity. Plaintiff also states, incongruously, that Astrazeneca Pharmaceuticals LP is “incorporated in” New York, and has its principal place of business in New York. But see, e.g., Astrazeneca Pharm. LP v. Intellipharmaceuticals Corp.,

Free access — add to your briefcase to read the full text and ask questions with AI

Gaines v. AstraZeneca Pharmaceutical, (S.D.N.Y. 2021).

Gaines v. AstraZeneca Pharmaceutical (Gaines v. AstraZeneca Pharmaceutical) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hertz Corp. v. Friend
559 U.S. 77 (Supreme Court, 2010)
Coppedge v. United States
369 U.S. 438 (Supreme Court, 1962)
Carden v. Arkoma Associates
494 U.S. 185 (Supreme Court, 1990)
Matsushita Electric Industrial Co. v. Epstein
516 U.S. 367 (Supreme Court, 1996)
Wisconsin Department of Corrections v. Schacht
524 U.S. 381 (Supreme Court, 1998)
Salahuddin v. Cuomo
861 F.2d 40 (Second Circuit, 1988)
Hill v. Curcione
657 F.3d 116 (Second Circuit, 2011)
Palazzo v. Corio
232 F.3d 38 (Second Circuit, 2000)
Abbas v. Dixon
480 F.3d 636 (Second Circuit, 2007)
Proctor v. LeClaire
715 F.3d 402 (Second Circuit, 2013)
L.A.M. Recovery, Inc. v. Department of Consumer Affairs
345 F. Supp. 2d 405 (S.D. New York, 2004)
Americold Realty Trust v. ConAgra Foods, Inc.
577 U.S. 378 (Supreme Court, 2016)
Brown Media Corporation v. K&L Gates, LLP
854 F.3d 150 (Second Circuit, 2017)
Cuoco v. Moritsugu
222 F.3d 99 (Second Circuit, 2000)